Sinovac Research And Development Co., Ltd.

This completed phase 1b trial tested a new 13-valent pneumococcal conjugate vaccine (PCV13) in 140 healthy infants (2 months old) and children (2-5 years). The goal was to check safety and immune response compared to an existing vaccine. Researchers monitored side effects and ant…